ASCO 2026 Highlights

LUNG - ASCO 2026 HIGHLIGHTS Treatment / Study Patient Population Key Findings Comparator Selpercatinib - EFS (stage II-IIIA): HR 0.17 (p0.001); LIBRETTO-432 Stage IB-IIIA RET fusion-positive NSCLC after vs. -24-mo EFS 92% vs. 61% definitive therapy (n=151) Placebo (adjuvant, up to 3 - AEs: ALT/AST elevation, hyperbilirubinemia, years) diarrhea, dry mouth, cough - mPFS: NR VS. 9.1 mos (HR 0.19); 7-yr PFS 55% vs. 3% Lorlatinib - No new intracranial progression after 30 mos on Stage IIIB/IV ALK+ unresectable NSCLC, vs. CROWN Update lorlatinib treatment-naive (n=296) Crizotinib (7-year follow- - IC progression HR 0.06 up) - OS data not yet mature Amivantamab CHRYSALIS-2 Atypical EGFR-mutated advanced NSCLC (G719X, - mOS: 41.0 mos (95% CI, 27.7-NE) + (Cohort C) S7681, L861Q), treatment-naive (n=49) - ORR 57%; mPFS 19.5 mos; mDoR 20.7 mos Lazertinib - mOS: 27.9 vs. 23.7 mos (HR 0.66, p=0.0017) Ivonescimab + Chemo Advanced squamous NSCLC, no prior systemic - mPFS: 11.1 VS. 6.9 mos (HR 0.60, p0.0001) HARMONi-6 VS. therapy, no EGFR/ALK (n=532) - AE: alopecia, anemia, leukopenia, hypoaesthesia, Tislelizumab + Chemo AST/ALT incline; China-only trial ONC Website: Brothe X @OncBrothers www.oncbrothers.com

GU - ASCO 2026 HIGHLIGHTS Study Patient Population Treatment / Comparator Key Findings Perioperative Apalutamide + High-risk localized - Dual primary endpoint met: MFS by BICR HR 0.80 (p=0.02) ADT PROTEUS - EFS: HR 0.71 (p 0.0001) prostate cancer vs. - Time to first subsequent therapy: HR 0.65 (p 0.0001) N=2,109 Placebo + ADT - 29% reduction in risk of oncologic event or death - rPFS: HR 0.481 (p 0.0001) - 24-mo rPFS 76.6% vs. 56.2% HRR gene-altered Talazoparib + Enzalutamide - BRCAm subgroup: HR 0.368 (p 0.0001) (24-mo rPFS 77.2% TALAPRO-3 mCSPC vs. vs. 48.8%) N=599 Placebo + Enzalutamide - Non-BRCAm subgroup: HR 0.667 (p=0.0022) (24-mo rPFS 76.2% vs. 60.2%) - AEs: anemia (71%), fatigue (28%), neutropenia (27%) Enfortumab vedotin + Untreated locally Pembrolizumab (EV+P) advanced/metastatic - Updated mOS: 33.6 mo vs. 15.9 mo (HR 0.53) EV-302 Update vs. urothelial carcinoma - ORR: 67.5% vs. 44.2% (CR: 30.4% vs. 14.5%) Gemcitabine + N=886 Cisplatin/Carboplatin RECENT GU FDA APPROVALS Durvalumab + BCG - DFS: HR 0.68 (95% CI 0.50-0.93, p=0.0154) High-risk, BCG-naive (Induction + Maintenance) 24-mo DFS: 87% vs. 82%; median DFS: NR in both arms POTOMAC NMIBC vs. OS: HR 0.80 (95% CI 0.53-1.20); median OS NR in both arms N=1,018 BCG (Induction + - Median follow-up: 60.7 months Maintenance) Capivasertib + - rPFS: 33.2 vs. 25.7 mo (HR 0.81, p=0.034) De novo mHSPC, PTEN- Abiraterone + ADT - OS: not yet mature (HR 0.90, NS) CAPItello-281 deficient (≥90% IHC loss) vs. - Grade ≥3 AEs: 67.0% vs. 40.4% N=1,012 Placebo + Abiraterone + - AE leading to discontinuation of capi/pbo: 18.3% vs. 4.8% ADT Adjuvant Belzutifan + Intermediate-high / high- - DFS: HR 0.72 (95% CI 0.59-0.87, p=0.0003) Pembro LITESPARK-022 risk resected clear cell RCC - 30-mo DFS: 75.8% vs. 68.6% VS. N=1,841 - Median DFS: NR in either arm Adjuvant Pembro ONC Website: Brothere X @OncBrothers www.oncbrothers.com

GI ASCO 2026 HIGHLIGHTS Treatment / Study Patient Population Key Findings Comparator Unresectable HCC, no prior STRIDE + Lenva + TACE (Arm A) vs. - mPFS: STRIDE+TACE 12.9 mo vs. TACE 8.1 mo (HR 0.71, p=0.0062) systemic therapy, ECOG PS 0-1, EMERALD-3 STRIDE + TACE (Arm B) - ORR (BICR): 38.9% (STRIDE+L+TACE) vs. 40.8% (STRIDE+TACE) vs. 27.0% (TACE) Child-Pugh A vs. - AEs: hypothyroidism, hypertension, diarrhea most common with STRIDE + L +TACE N=760 TACE alone (Arm C) Unresectable Pemigatinib 13.5 mg daily - mPFS: 8.34 mo vs. 6.80 mo (HR 0.584, p=0.0078) cholangiocarcinoma with FIGHT-302 vs. - mOS: 24.4 mo vs. 25.0 mo (HR 1.095, p=0.6581) FGFR2 rearrangements Gemcitabine + Cisplatin - AEs: hyperphosphatemia (81.9%), alopecia, stomatitis, PPES N=167 ctDNA-positive: Adjuvant chemo - ctDNA prognostic: 3-yr DFS 87% (ctDNA-neg) vs. 38% (ctDNA+ OBS), HR 6.32 (p<0.001) Stage II colon cancer, CIRCULATE vs. - 3-yr OS: 98% vs. 84% (HR 7.14, p=0.001) ctDNA-guided Update Observation - Chemo reduced 3-yr recurrence: 19% vs. 62% (HR 0.23, p=0.009) adjuvant therapy ctDNA-negative: Off-study - DFS (ITT): chemo 61% vs. ctDNA+ OBS 38% (HR 0.55, p=0.12) - EFS benefit in patients completing all treatment: HR 0.63 (0.41-0.97) Stage II-IVA Durvalumab + FLOT - Neoadjuvant + surgery only (no adjuvant): median EFS 22.83 VS. 10.55 mo (HR 0.69) MATTERHORN resectable gastric/ (perioperative) - Neoadjuvant + surgery + started adjuvant: median EFS 21.88 vs.14.09 mo (HR 0.65) GEJ adenocarcinoma VS. Update - Durvalumab did not delay surgery N=948 Placebo + FLOT - AEs comparable Website: X @OncBrothers www.oncbrothers.com

HEAD & NECK AND SARCOMA - ASCO 2026 HIGHLIGHTS Study Patient Population Treatment / Comparator Key Findings HEAD & NECK Docetaxel + Carboplatin Carbo vs. Stage III-IVa locally induction Carboplatin CRT - 3-yr FFS: 84.8% VS. 86.8% (HR 1.15, p=0.584); non-inferiority met (p=0.013) Cis Induction advanced NPC, age 18-65, VS. - 3-yr OS: 96.2% VS. 97.4% (HR 0.85) in NPC KPS >70 Docetaxel + Cisplatin induction - 3-yr DMFS: 91.0% VS. 89.6% (HR 1.59) - Cisplatin CRT R/M HNSCC, post-PD-(L)1 + - ORR: primary endpoint (single-arm) Amivantamab OrigAMI-4 platinum chemo, no prior anti- - Median PFS: 6.8 mos (95% CI 5.2-8.3) monotherapy EGFR, pl6+ OPC excluded - Median OS: 12.5 mos (95% CI 10.2-16.8) SARCOMA Advanced / metastatic Abemaciclib 200 mg PO BID - PFS: 9.7 VS. 1.5 mos (HR 0.38, p 0.001) SARC041 VS. dedifferentiated liposarcoma Placebo (crossover allowed) - OS: NR VS. 25.5 mos (HR 0.55, p=0.07) Locally advanced, unresectable, or Bezuclastinib 600 mg + Sunitinib 37.5 mg - PFS: 16.5 VS. 9.2 mos (HR 0.50, p 0.0001) PEAK metastatic GIST; post-imatinib VS. - TEAEs >20% in both arms; diarrhea, ALT/AST increase, HTN more common with combo progression/intolerance Sunitinib 37.5 mg alone ONC Website: Brothe X @OncBrothers www.oncbrothers.com